Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Shares Up 0.3%

Fresenius Medical Care AG & Co. KGaA (NYSE:FMSGet Rating)’s share price shot up 0.3% during trading on Monday . The stock traded as high as $26.83 and last traded at $26.80. 2,655 shares traded hands during mid-day trading, a decline of 99% from the average session volume of 495,857 shares. The stock had previously closed at $26.73.

Several research firms have recently commented on FMS. Oddo Bhf raised Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “outperform” rating and set a €72.00 ($77.42) target price on the stock in a research report on Tuesday, March 1st. Credit Suisse Group decreased their target price on Fresenius Medical Care AG & Co. KGaA from €66.00 ($70.97) to €61.00 ($65.59) in a research report on Tuesday, March 1st. JPMorgan Chase & Co. increased their price target on Fresenius Medical Care AG & Co. KGaA from €48.70 ($52.37) to €51.00 ($54.84) and gave the stock an “underweight” rating in a research report on Thursday, May 5th. StockNews.com began coverage on Fresenius Medical Care AG & Co. KGaA in a research report on Tuesday, May 10th. They set a “buy” rating on the stock. Finally, Berenberg Bank reduced their price target on Fresenius Medical Care AG & Co. KGaA from €84.90 ($91.29) to €83.40 ($89.68) in a research report on Thursday, March 17th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, Fresenius Medical Care AG & Co. KGaA has an average rating of “Hold” and an average target price of $53.71.

The stock has a fifty day simple moving average of $31.10 and a two-hundred day simple moving average of $31.94. The stock has a market cap of $15.67 billion, a price-to-earnings ratio of 15.27, a P/E/G ratio of 1.07 and a beta of 1.17. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.93 and a current ratio of 1.26.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMSGet Rating) last issued its earnings results on Wednesday, May 4th. The company reported $0.38 earnings per share for the quarter, beating analysts’ consensus estimates of $0.30 by $0.08. Fresenius Medical Care AG & Co. KGaA had a return on equity of 6.99% and a net margin of 4.91%. The firm had revenue of $5.10 billion for the quarter, compared to the consensus estimate of $4.97 billion. Equities analysts expect that Fresenius Medical Care AG & Co. KGaA will post 1.99 earnings per share for the current fiscal year.

The company also recently declared an annual dividend, which was paid on Friday, May 27th. Stockholders of record on Monday, May 16th were paid a $0.7093 dividend. This represents a dividend yield of 3.4%. The ex-dividend date of this dividend was Friday, May 13th. Fresenius Medical Care AG & Co. KGaA’s payout ratio is 28.00%.

Institutional investors and hedge funds have recently made changes to their positions in the company. Commonwealth Equity Services LLC lifted its stake in shares of Fresenius Medical Care AG & Co. KGaA by 6.4% in the 4th quarter. Commonwealth Equity Services LLC now owns 13,583 shares of the company’s stock valued at $440,000 after acquiring an additional 817 shares during the last quarter. Atlas Capital Advisors LLC lifted its stake in shares of Fresenius Medical Care AG & Co. KGaA by 27.1% in the 4th quarter. Atlas Capital Advisors LLC now owns 9,266 shares of the company’s stock valued at $301,000 after acquiring an additional 1,973 shares during the last quarter. UMB Bank N A MO bought a new position in Fresenius Medical Care AG & Co. KGaA during the 4th quarter worth $192,000. Legacy Wealth Asset Management LLC raised its position in Fresenius Medical Care AG & Co. KGaA by 283.2% during the 4th quarter. Legacy Wealth Asset Management LLC now owns 36,892 shares of the company’s stock worth $1,198,000 after purchasing an additional 27,264 shares during the last quarter. Finally, Alan B. Lancz & Associates Inc. bought a new position in Fresenius Medical Care AG & Co. KGaA during the 4th quarter worth $196,000. Institutional investors own 4.73% of the company’s stock.

About Fresenius Medical Care AG & Co. KGaA (NYSE:FMS)

Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

Featured Stories

Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.